Evidence map›Paper›PMID 40613841›Full record

ReviewMycopathologia2025

Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.

Isabela Lima Miranda, Nalu Teixeira Aguiar Peres, Rafael Wesley Bastos, Luana Rossato, Florent Morio, Daniel Assis Santos

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Catheter-AssociatedJournal of fungi (Basel, Switzerland) · 2026
    Article
  3. InvasiveJournal of fungi (Basel, Switzerland) · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Isabela Lima MirandaDepartamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil.
Nalu Teixeira Aguiar PeresDepartamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil.
Rafael Wesley BastosNational Institute of Science and Technology in Human Pathogenic Fungi, Ribeirão Preto, Brazil.
Luana RossatoLaboratório de Pesquisa em Ciências da Saúde, Universidade Federal da Grande Dourados, Mato Grosso do Sul, 79804-970, Brazil.
Florent MorioNantes Université, CHU Nantes, Cibles et Médicaments des Infections et de l'Immunité, IICiMed, UR 1155, 44000, Nantes, France.
Daniel Assis SantosDepartamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil. das@ufmg.br.ORCID http://orcid.org/0000-0002-1108-5666

Funding

Brazilian Ministry of Health 444501/2023-1CAPES-COFECUB program Código de Financiamento 001Conselho Nacional de Desenvolvimento Científico e Tecnológico 408540/2022-2Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.966527/2024-00National Institute of Science and Technology INCT Funvir from Brazil 303762/2020-9
6 · The paper itself

Abstract

Trichosporon spp. are ubiquitous environmental and emerging opportunistic fungi that can be part of the normal microbiota of the skin, vagina, and gastrointestinal tract in humans and other animals. In a state of microbiota imbalance, both immunocompromised and non-immunocompromised patients are susceptible to trichosporonosis, which can present as either superficial infections, such as White Piedra, or deep-seated infections, such as fungemia. Due to intrinsic resistance or limited efficacy reported with fluconazole, polyenes, echinocandins, and flucytosine, voriconazole is currently recommended in clinical guidelines. Biofilm formation and the overexpression of efflux pumps may contribute to this limited efficacy, but other resistance mechanisms have also been reported. The high antifungal resistance levels present in this genus highlight the urgent need for new therapeutic approaches and a better understanding of Trichosporon pathogenesis and the molecular mechanisms underlying this resistance. In this review, we discuss antifungal resistance and the mechanisms of this resistance in Trichosporon spp., addressing key points that require further investigation.

Indexed as

Antifungal AgentsDrug Resistance, FungalTrichosporonTrichosporonosisAnimalsHumansAntifungal AgentsAntifungal resistanceMechanism resistanceReviewTrichosporon spp.

Identifiers

PMID40613841

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.